Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ: NTRA) reported initial translational results from the Phase III PALLAS trial showing that Signatera MRD testing after surgery strongly stratifies distant recurrence risk in stage II–III HR+/HER2- breast cancer.
In a U.S. biomarker cohort of 420 patients, ~92% were MRD-negative at baseline with a 5-year DRFI of 93%, while baseline MRD-positive (~8%) had a 5-year DRFI of 28% (HR ~15). At end of treatment, MRD-negative 5-year DRFI was 95% and MRD-positive 32% (HRs >20). MRD status at baseline, ~6 months, and EOT was consistently highly prognostic versus clinicopathologic factors.
Natera (NASDAQ: NTRA) presented two oral analyses at the ASH Annual Meeting showing clinical utility of personalized ctDNA testing in lymphoma.
Key highlights: Signatera detected ctDNA pre-treatment in 94% of 144 patients across 14 lymphoma subtypes and showed ctDNA clearance strongly predicted CAR-T response (p=0.0028); rapid clearance after one chemotherapy cycle had HR 20.95 versus 7.45 for delayed clearance. Signatera end-of-1L status was highly prognostic for event-free survival (HR 49.77, p<0.0001). The HOVON study using CLARITY (166 DLBCL patients) found post-negative surveillance relapse-free probability of 99% at 6 months and 97% at 12 months.
Natera (NASDAQ: NTRA) completed an all-stock acquisition of Foresight Diagnostics to expand its personalized MRD offerings and lymphoma capabilities. The deal values Foresight at up to $450 million ( $275M upfront plus $175M in earnouts tied to revenue and reimbursement milestones). Foresight’s PhasED-Seq phased-variant technology reports LOD95 of 0.3 ppm and detection below 0.1 ppm, and the technology will be integrated into Natera’s Signatera platform for research use immediately and for clinical launch in 2026. Foresight CLARITY MRD assay and recent inclusion of ctDNA MRD in NCCN lymphoma guidance support clinical momentum.
Natera (NASDAQ: NTRA) will present new Signatera data at the 2025 American Society of Hematology (ASH) Annual Meeting, December 6-9 in Orlando. Four abstracts report Signatera clinical validity and utility in hematologic malignancies, including a retrospective real-world cohort of 144 lymphoma patients showing personalized ctDNA predicted outcomes, detected recurrence earlier than imaging, and clarified ambiguous scans.
Presentations also cover ctDNA MRD monitoring after autologous transplant in multiple myeloma and WGS/WES-based ctDNA methods for DLBCL molecular subtyping. One oral talk is Dec 6 at 2:45 PM ET.
Natera (NASDAQ: NTRA) will present at the 2025 San Antonio Breast Cancer Symposium (Dec 9–12) with at least 12 abstracts covering Signatera results from >50,000 patients across real-world and prospective studies.
Key disclosed findings include a Signatera Genome surveillance cohort (n=227) with reported 100% sensitivity and specificity for detecting recurrence, aSignatera-positive within 3 months post-surgery associated with higher distant recurrence risk (HR 13.1, 95% CI 1.4–122.1, P=0.005), and Signatera positivity post-treatment linked to worse distant recurrence-free survival (HR 221.2, 95% CI 131.0–373.4, P <0.0001). LEADER phase 2 data show sustained MRD negativity with 12-month NPV RFS=99% and DRFS=100% and delayed distant recurrence for MRD-positive patients treated with ribociclib (18.6 vs 5.4 from treatment start).
Natera (NASDAQ: NTRA) reported that employees contributed more than 1,500 volunteer hours during its fourth annual Volunteer Month in October, organized by employee group Natera Nurtures.
Key activities included sorting 5,600+ pounds of food (equivalent to 4,725 meals) in Austin, serving 120 Ronald McDonald House guests in the Bay Area, 50+ volunteers making fleece blankets in San Carlos and Pleasanton, blood donations helping 100+ patients, care-kit assemblies, animal-shelter support, and community cleanups.
Since 2021, employees have logged 28,500+ volunteer hours, surpassing the company’s five-year target of 20,000 hours by end of 2025.
Natera (NASDAQ: NTRA) announced on November 12, 2025 that its oncology testing portfolio, including Signatera, is integrated into Flatiron Health’s cloud-based OncoEMR platform.
The two-way integration enables electronic ordering and results delivery inside the EMR for over 4,500 cancer care providers and roughly 1,000 community-based locations across the U.S., streamlining molecular residual disease (MRD) testing and monitoring within clinicians’ workflows.
Natera (NASDAQ: NTRA) reported Q3 2025 revenue of $592.2M, up 34.7% year-over-year, and raised 2025 revenue guidance to $2.18B–$2.26B. Gross margin improved to 64.9% and the company processed approximately 893,600 tests in Q3, a 15.2% increase. Oncology tests rose ~53.9% year-over-year with record sequential clinical MRD growth. Natera achieved positive cash flow of approximately $26.4M in the quarter, held about $1.042B in cash and equivalents, and reported total debt of $80.3M.
However, operating expenses increased 54.9%, driving a Q3 net loss of $87.5M (loss per share $0.64) and weighted average shares outstanding rose to 137.2M.
Natera (NASDAQ: NTRA) will expand its Fetal Focus single-gene NIPT from the initial 5-gene panel to a 20-gene panel, with the expanded test launching in Q4 2025. The assay uses Natera's LinkedSNP™ technology to detect challenging homozygous fetal mutations from maternal cfDNA.
Anecdotally, Fetal Focus identified a pregnancy homozygous for the delta F508 cystic fibrosis mutation that another laboratory missed. Natera initiated the prospective EXPAND trial in 2023; EXPAND has enrolled approximately 1,700 patients with genetic confirmation of all outcomes and reported an initial readout where Fetal Focus identified 5 of 5 homozygous cases.
Natera (NASDAQ: NTRA) will release its third quarter 2025 financial results for the period ended September 30, 2025 after market close on November 6, 2025. The company will host a conference call and webcast the same day at 4:30 p.m. ET. Live dial-in numbers and a conference ID are provided, and a webcast replay will be available at the company's investor website.
- Event: Third Quarter 2025 Financial Results
- Date & Time: November 6, 2025 at 4:30 p.m. ET
- Webcast: https://events.q4inc.com/attendee/822764987